New Dual-Action drug shows promise in advanced lung cancer trial
NCT ID NCT04900363
First seen Mar 04, 2026 · Last updated May 11, 2026 · Updated 9 times
Summary
This trial tested a new drug called AK112 in 108 people with advanced non-small cell lung cancer (stage IIIB/C or IV) whose tumors had a PD-L1 score of 1% or higher. The drug is a bispecific antibody that targets both PD-1 and VEGF to help the immune system fight cancer and block tumor blood supply. The main goals were to see how many patients' tumors shrank or disappeared, how long that lasted, and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.